OD
ODTC.US Odonate Therapeutics
- Market cap
- USD 53.4M
- P/E
- 7.4x
- P/B
- 0.49x
- ROE
- 6.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2023.
Is ODTC.US undervalued?
Graham numberODTC.US trades 59.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Odonate Therapeutics fundamental analysis
No fundamental analysis for Odonate Therapeutics yet.
Odonate Therapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Odonate Therapeutics
Odonate, Inc., has no significant operations. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
Full company profileOdonate Therapeutics financial statements
Odonate Therapeutics annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -20.0K | -350K | -381K | -870K | -1.05M | -342K | -21.0K |
| Operating Income | -158K | -3.09M | -32.7M | -90.8M | -115M | -127M | -46.8M | -3.92M | -817K |
| EBITDA | -158K | -3.09M | -32.7M | -88.6M | -111M | -126M | -67.3M | 9.98M | 9.47M |
| Net Income | -158K | -3.09M | -32.7M | -89.0M | -112M | -126M | -68.3M | 42.9M | 7.33M |
| EPS | -151 | -2,955 | -61,665 | -97,012 | -107,939 | -102,557 | -48,901 | 39,322 | 6.81 |
| Balance Sheet | |||||||||
| Total Assets | 140K | 2.88M | 203M | 143M | 189M | 168M | 79.0M | 104M | 110M |
| Total Liabilities | 29.0K | 598K | 7.51M | 18.7M | 26.5M | 31.7M | 19.7M | 2.88M | 2.33M |
| Shareholders' Equity | 111K | 2.28M | 196M | 124M | 162M | 136M | 59.3M | 101M | 108M |
| Cash & Short-term Investments | 138K | 2.60M | 198M | 139M | 180M | 157M | 68.9M | 48.2M | 57.0M |
| Total Debt | - | - | - | - | 2.06M | 5.33M | 4.67M | 2.77M | 2.30M |
| Cash Flow | |||||||||
| Operating Cash Flow | -165K | -1.73M | -25.9M | -67.1M | -96.6M | -113M | -75.7M | 1.80M | 8.74M |
| Capital Expenditure | 0.00 | 0.00 | 83.0K | 1.91M | 166K | 432K | 26.0K | 0.00 | 0.00 |
| Free Cash Flow | -165K | -1.73M | -25.9M | -69.0M | -96.8M | -114M | -75.8M | 1.80M | 8.74M |
| Ratios | |||||||||
| ROE | -142.3% | -135.1% | -16.7% | -71.7% | -68.9% | -92.8% | -115.3% | 42.6% | 6.8% |
| ROA | -112.9% | -107.1% | -16.1% | -62.4% | -59.2% | -75.3% | -86.5% | 41.4% | 6.6% |
| Debt to Equity | - | - | - | - | 0.01x | 0.04x | 0.08x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Odonate Therapeutics dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | USD 791K | 758 | - |
| 2015 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:8 on Jan 15, 2025.
Who owns Odonate Therapeutics
Ownership data of Odonate Therapeutics is not available yet.
Odonate Therapeutics company profile
- Company name
- Odonate Therapeutics
- Ticker
- ODTC.US
- Exchange
- USA Stocks
- Listed since
- Dec 7, 2017
- Sector
- Financial Services
- Industry
- Capital Markets
- Employees
- 137
- Fiscal year end
- December
- Address
- 3 East 28th Street, New York, NY, United States, 10016
- Phone
- 332 206 0935
- Website
- odonate.com
About Odonate Therapeutics
Odonate, Inc., has no significant operations. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
Odonate Therapeutics management
3- Mr. Kevin C. TangChairman & CEO · born 1967
- Mr. Michael S. Hearne CPACFO & Principal Accounting Officer · born 1963
- Dr. Steven S. Pfeiffer Ph.D.Senior Vice President of Technical Operations · born 1976